A Study of Brivaracetam in Subjects With Partial Onset Seizures

PHASE2CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Epilepsy, Focal
Interventions
OTHER

Placebo

Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)

DRUG

Brivaracetam

Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)

DRUG

Brivaracetam

Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)

Trial Locations (56)

Unknown

Bruges

Brussels

Duffel

Edegem

Leuven

Liège

Beroun

Brno

České Budějovice

Prague

Kuopio

Oys (Oulu)

Tampere

Angers

Béthune

Dijon

Grenoble

Lille

Lyon

Marseille

Montpellier

Nancy

Paris

Rennes

Strasbourg

Tain-l'Hermitage

Toulouse

Berlin

Bielefeld

Bonn

Chemnitz

Erlangen

Essen

Frankfurt

Freiburg im Breisgau

Kehl

München

Ulm

Heemstede

Heeze

Gdansk

Katowice

Lodz

Lublin

Szczecin

Warsaw

Madrid

Valencia

Vigo

Bucks

Cambridge

Cardiff

Glasgow

Hartshill

Liverpool

Newcastle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY